Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)

v3.22.2.2
Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Nov. 02, 2020
USD ($)
Feb. 25, 2019
USD ($)
agreement
Sep. 30, 2022
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Agreements            
Payments related to purchase of royalty rights and other commercial payment rights         $ 20,500  
Long-term royalty and commercial payment receivables     $ 66,049 $ 66,049   $ 69,075
Contingent consideration under RPAs and CPPAs     75 75   8,075
Impairment of long-term royalty receivable       0   0
Bioasis | Royalty Purchase Agreement            
Agreements            
Percentage of option to purchase royalty right on future license agreements   1.00%        
Number of future license agreements under optional purchase right | agreement   2        
Obligation upon exercise of options per licensed product, second agreement   $ 300        
Obligation upon exercise of options per licensed product, third agreement   400        
Payments related to purchase of royalty rights and other commercial payment rights   300        
Long-term royalty and commercial payment receivables   400        
Contingent consideration under RPAs and CPPAs   100 100 100    
Changes in estimated fair value of contingent consideration       0    
Payments of contingent consideration     $ 0 0    
Impairment of long-term royalty receivable       0   0
Bioasis | Royalty Purchase Agreement | Maximum            
Agreements            
Potential future cash payments   $ 200        
Bioasis | Second Royalty Purchase Agreement            
Agreements            
Payments related to purchase of royalty rights and other commercial payment rights $ 1,200          
Long-term royalty and commercial payment receivables $ 1,200          
Impairment of long-term royalty receivable       $ 0   $ 0